BREAKING NEWS: U.S. FDA OKs Lilly’s Ebglyss (Lebrikizumab-lbkz) for Adults and Children 12 Years and Older With Moderate-to-Severe AD September 13, 2024
Access Update: Amber Specialty Pharmacy Now Offers Galderma’s New IL-31 Blocker for Prurigo Nodularis Patients September 12, 2024